Edison Oncology和冠科美博（Apollomics）宣布EO1001(APL-122) I/IIa 期临床试验中首例患者接受治疗
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Oct 1, 2021 – (亚太商讯 via SEAPRWire.com) – Edison...
Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial
MENLO PARK, CA and HELSINKI, FINLAND, Oct 1, 2021 – (ACN Newswire via SEAPRWire.com) – Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the […]
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
FOSTER CITY, Calif. and HANGZHOU, China and MENLO PARK, CA, Feb 10, 2021 – (ACN Newswire) – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of […]